Note,
The Mozart effect in chronic myeloid leukaemia
Affiliations
- [1] Aarhus University Hospital [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD]
Abstract
Clinical research has not been able to establish whether the differences between first- and second-generation BCR-ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by Alcazer et al., a relevant difference seems to emerge—paradoxically in the absence of the drugs—as demonstrated by differences in the relapse kinetics after cessation of therapy. Commentary on: Alcazer et al. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. Br J Haematol 2024;204:1536-1539.
Keywords
BCR-ABL 1,
chronic myeloid leukaemia,
kinase inhibitors,
treatment-free remission